BROOKE ENDERLE: Open Payments
NPI 1700461290 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,306 in 64 payments from 16 companies in 2025. Trend: 2023 $1,492 · 2024 $1,298 · 2025 $1,306
Food & beverage: $1,306
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $247 |
| Otsuka America Pharmaceutical, Inc. | 10 | $161 |
| Indivior Inc. | 6 | $141 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $140 |
| ANI Pharmaceuticals, Inc. | 4 | $124 |
| Astellas Pharma US Inc | 3 | $70 |
| Abbott Laboratories | 3 | $68 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $64 |
| Lilly USA, LLC | 3 | $62 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
Products named: REXULTI, SUBLOCADE, CAPLYTA, PURIFIED CORTROPHIN GEL, Wegovy, Veozah, Rybelsus, FREESTYLE LIBRE 3.
Industry payments across DE — which companies pay providers there.
